Evidence map›Paper›PMID 35447911›Full record

ArticleMarine drugs2022

5-

Darinthip Suksamai, Satapat Racha, Nicharat Sriratanasak, Chatchai Chaotham, Kanokpol Aphicho, Aye Chan Khine Lin, Chaisak Chansriniyom, Khanit Suwanborirux, Supakarn Chamni, Pithi Chanvorachote

Open access · goldAbstract read
In one paragraph

Article in Marine drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Darinthip SuksamaiCenter of Excellence in Cancer Cell and Molecular Biology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
Satapat RachaInterdisciplinary Program in Pharmacology, Graduate School, Chulalongkorn University, Bangkok 10330, Thailand.
Nicharat SriratanasakCenter of Excellence in Cancer Cell and Molecular Biology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
Chatchai ChaothamCenter of Excellence in Cancer Cell and Molecular Biology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
Kanokpol AphichoNatural Products and Nanoparticles Research Unit (NP2), Chulalongkorn University, Bangkok 10330, Thailand.ORCID 0000-0002-4607-1061
Aye Chan Khine LinGraduate Program of Pharmaceutical Science and Technology, Faculty of Pharmaceutical Science, Chulalongkorn University, Bangkok 10330, Thailand.
Chaisak ChansriniyomNatural Products and Nanoparticles Research Unit (NP2), Chulalongkorn University, Bangkok 10330, Thailand.
Khanit SuwanboriruxNatural Products and Nanoparticles Research Unit (NP2), Chulalongkorn University, Bangkok 10330, Thailand.
Supakarn ChamniNatural Products and Nanoparticles Research Unit (NP2), Chulalongkorn University, Bangkok 10330, Thailand.ORCID 0000-0002-8941-1046
Pithi ChanvorachoteCenter of Excellence in Cancer Cell and Molecular Biology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
Chulalongkorn University · TH

Funding

National Research Council of Thailand (NRCT) N41A640075
6 · The paper itself

Abstract

Cancer stem cells (CSCs) drive aggressiveness and metastasis by utilizing stem cell-related signals. In this study, 5-

Indexed as

Lung NeoplasmsProto-Oncogene Proteins c-aktAlanineApoptosisCell Line, TumorCell ProliferationHumansNeoplastic Stem CellsTetrahydroisoquinolinesTumor Suppressor Protein p53AlanineProto-Oncogene Proteins c-aktrenieramycin TTetrahydroisoquinolinesTumor Suppressor Protein p535-O-(N-Boc-l-alanine)-renieramycin TAktanti-cancerapoptosiscancer stem cellsc-Myclung cancermarine spongeXestospongia sp.

Identifiers

PMID35447911
PMCPMC9029977
OpenAlexW4220675860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.